Published March 5, 2022 | Version v1
Journal article Metadata-only

The Impact of Radiation Therapy in Children and Adolescents With Metastatic Rhabdomyosarcoma

Creators

  • 1. F. Hoffmann-La Roche Ltd, Basel (Switzerland)
  • 2. Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Italy)
  • 3. Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, University Paris-Saclay, INSERM U1015, Villejuif (France)
  • 4. Department of Oncology, University College London Hospitals NHS Foundation Trust, London (United Kingdom)

Description

There is limited evidence to define the role of radiation therapy in children with metastatic rhabdomyosarcoma (mRMS). In the international BERNIE study, children with mRMS or non-RMS soft tissue sarcoma were randomized to receive standard chemotherapy with or without bevacizumab, with radiation therapy to all disease sites recommended after chemotherapy cycle 6. We retrospectively evaluated the impact of radiation therapy on survival in the mRMS cohort.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2021.06.031

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2021.06.031;
PII
S0360301621008233;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
111
Journal Issue
4
Journal Page Range
p. 968-978
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
53122315
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ADOLESCENTS; ANIMAL TISSUES; CHEMOTHERAPY; CHILDREN; METASTASES; RADIOTHERAPY; RHABDOMYOSARCOMAS
Descriptors DEC
AGE GROUPS; ANIMALS; BODY; DISEASES; HUMANS; MAMMALS; MEDICINE; MYOSARCOMAS; NEOPLASMS; NUCLEAR MEDICINE; PRIMATES; RADIOLOGY; SARCOMAS; THERAPY; VERTEBRATES

Optional Information

Copyright
Copyright (c) 2021 Elsevier Inc. All rights reserved.
Collaborations
European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) and the European Innovative Therapies for Children with Cancer (ITCC) Consortium